Skip to main content

Table 1 Input parameters of base case, including survival probabilities, utilities and costs

From: Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation

Parameters Mean SE Distribution Source
Survival probabilities per year
Ipilimumab
 PFS 0.175 0.012 Beta [6]
 OS 0.366 0.018 Beta [6]
 TIL
 PFS 0.234 0.089a Beta [10, 11]
 OS 0.412 0.098a Beta [10, 11]
Utilities and side effects
Ipilimumab
 Stable disease 0.850 0.020 Beta [18]
 Progression 0.590 0.020 Beta [18]
TIL
 Stable disease 0.850 0.020 Beta [18]
 Progression 0.590 0.020 Beta [18]
Utility decrements
 Fatigue 0.090 0.020 Beta [18]
 Diarrhea 0.060 0.020 Beta [18]
 Colitis 0.130 0.020 Beta [18]
 Neutropenia 0.130 0.020 Beta [18]
 Dyspnea 0.100 0.020 Beta [18]
 Flu-like syndrome (grade I/II)) 0.090 0.020 Beta [18]
 Anaemia 0.110 0.020 Beta [18]
Likelihood of side effects
Ipilimumab
 Fatigue 0.070 0.015 Beta [6]
 Diarrhea 0.060 0.015 Beta [6]
 Colitis 0.060 0.015 Beta [6]
 Dyspnea 0.040 0.015 Beta [6]
 Immune 0.100 0.015 Beta [6]
 Anaemia 0.030 0.015 Beta [6]
TILa
 Fatigue 0.001 0.001 Beta [24]
 Diarrhea 0.001 0.001 Beta [24]
 Neutropenia 0.560 0.100 Beta [24]
 Dyspnea 0.020 0.015 Beta [24]
 Immune 0.220 0.100 Beta [24]
 Anaemia 0.440 0.100 Beta [24]
Failures, non-compliance TIL
 Failures 0.100 0.015 Beta [20], Expert opinion
 Non-compliance 0.100 0.015 Beta [21]
Costs in euros
Costs of ipilimumab total 91,487.50 +/-25% Gamma  
 Drug 90,100.00 +/-25% Gamma [22]
 Administration 473.00 +/-25% Gamma [23]
 Management of side effects 914.50 +/-25% Gamma [6, 16]
Costs of TIL total 62,000.00 +/-25% Gamma NKI-AVL
 TIL-production-totalb 35,500.00 +/-25% Gamma NKI-AVL
 Personnel 18,000.00 +/-25% Gamma NKI-AVL
 Material and quality control 10,000.00 +/-25% Gamma NKI-AVL
 Cleanroom and equipment 7,500.00 +/-25% Gamma NKI-AVL
 TIL-hospital-total 26,500.00 +/-25% Gamma NKI-AVL
 admission 13,000.00 +/-25% Gamma NKI-AVL
 Preparatory surgery 6,500.00 +/-25% Gamma NKI-AVL
 Side-effects, medication, monitoring 6,500.00 +/-25% Gamma NKI-AVL
Costs of follow-up stable diseasec 516.00 +/-25% Gamma [25]
Costs progressive diseased 9,125.00 +/-25% Gamma [31]
Costs of side effects for ipilimumab
 Fatigue 198.00 +/-25% Gamma [16]
 Diarrhea 580.00 +/-25% Gamma [16]
 Colitis/neutropeniae 1115.00 +/-25% Gamma [16]
 Dyspnea 100.00 +/-25% Gamma Assumption
 Immune 7,680.00 +/-25% Gamma [16]
 Anaemia 898.00 +/-25% Gamma [16]
  1. aModeled in the first cycle of “stable disease”
  2. bbased on 10 TIL productions per year
  3. cbased on 4a follow-up visit physician+CT scan (stable)
  4. dcost for palliative care or end-stage disease care was based on the per diem cost of a palliative care unit
  5. eresembles 2-5 days hospitalization for severe toxicity (grade III-IV)
  6. PFS: Progression Free Survival, OS: Overall Survival; SE: Standard Error; NKI-AVL: Netherlands Cancer Institute-Antoni van Leeuwenhoek hospital
  7. Input cost price calculation NKI-AVL: based on N= 10 patients from the pilot study
  8. Inclusion criteria of the pilot study were: a resectable metastasis of at least 2-3cm; a sufficient heart, lung and kidney function; a maximum of 2 asymptomatic brain metastasis smaller than 1cm; not concurrently being treated with immune function-suppressing medication; not having auto-immune disorders; and a minimum expected life span of 3 months